MBX Biosciences, Inc. <MBX.O>: JP Morgan resumes coverage with overweight rating; target price $88
MBX•Related News
Nektar Therapeutics <NKTR.O>: JPMorgan resumes coverage with neutral rating; target price $65
NKTR•
First gas from Australia's Beetaloo puts shale ambition to the test
TBN•
AppLovin Corporation <APP.O>: Piper Sandler cuts target price to $325 from $385
APP•
Walmart Inc <WMT.O>: Telsey Advisory Group cuts target price to $130 from $140
WMT•
Coincheck Group publishes FY2026 annual report
CNCK•